Results

Lack of FPR2 or its Ligand Annexin A1 Accelerates Atherogenesis
To investigate the role of FPR2 in early atherosclerosis, we fed Apoe −/− and Apoe −/− Fpr2 −/− mice a HFD for 4 weeks and assessed atherosclerotic lesion sizes in aortic roots. Lack of FPR2 significantly increased lesion sizes ( Figure 1A ) characterized by increased cellularity and a matching increase in macrophage content (Figure 1B and 1C) . Although infrequent in atherosclerotic lesions, neutrophils were also found in larger numbers in plaques of Apoe
−/−
Fpr2
−/− mice ( Figure 1D ). In addition, no changes in the number of intercellular adhesion molecule-1 (ICAM-1) or vascular cell adhesion molecule-1 (VCAM-1)-expressing endothelial cells were found ( Figure 1E ), and the number of apoptotic cells as assessed by TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining was not different between the strains (Online Figure IA) . Finally, no differences were detected for counts of leukocyte subsets, plasma cholesterol, and triglyceride levels in Apoe −/− and Apoe −/− Fpr2 −/− mice (Online Table I ). These data are in striking contrast to the previously reported lesion phenotype of mice lacking the neutrophil-borne FPR2 ligand CRAMP (Cathelicidin-related Antimicrobial Peptide). 7 Thus, we hypothesized that resolution-inducing FPR2 ligands may hold an important role during early atherosclerosis and consequently studied the development of atherosclerosis in mice lacking the proresolving FPR2 ligand AnxA1. Apoe 
Annexin A1-FPR2 Axis Prevents Arterial Myeloid Cell Recruitment
The similarity of atherosclerotic lesion characteristics in Apoe −/− Fpr2 −/− and Apoe −/− Anxa1 −/− mice points toward the importance of an endogenous AnxA1-FPR2 axis preventing atherogenesis. To study the presence of AnxA1 in atherosclerotic lesions, we stained murine plaques with an antibody to AnxA1. We could evidence abundant, specific staining of AnxA1 in murine lesions of Apoe −/− mice, whereas no staining was observed in lesions Apoe −/− Anxa1 −/− mice ( Figure 2A ). To study the possible origin of AnxA1, we costained murine atherosclerotic lesions with an antibody recognizing AnxA1
Nonstandard Abbreviations and Acronyms and with antibodies toward macrophages (Mac2), neutrophils (Ly6G), smooth muscle cells (α-smooth muscle actin), or endothelial cells (von Willebrand Factor). Specific immunofluorescence was prominent in myeloid cells and in the endothelium, whereas scarce staining was found in smooth muscle cells ( Figure 2B ). Importantly, a similar distribution of AnxA1 staining was evidenced in human endarterectomy specimens (Online Figure IIA and IIB) . In addition, AnxA1 plasma levels showed no differences between Apoe −/− and Apoe −/− Fpr2 −/− mice ( Figure 2C ), and plasma AnxA1 levels were negatively correlated with lesion sizes in the aortic root of Apoe −/− mice, a relationship absent in Apoe −/− Fpr2 −/− mice ( Figure 2D ).
To assess the role of the AnxA1-FPR2 axis on arterial leukocyte recruitment, we performed intravital microscopy of the carotid artery. Herein, myeloid cells were visualized by administration of antibodies to Ly6G (neutrophils), Ly6C (classical monocytes), and CD11b (myeloid cells). Although tethering and rolling speed of myeloid cell subsets were not affected in mice lacking FPR2 or AnxA1 ( Figure 3D and 3E). Because endothelial adhesion molecule expression did not differ between the mouse strains and with the largely myeloid cell-restricted expression of FPR2, we suspected the adhesion defect to be leukocyte intrinsic. 
Anxa1
−/− mice were fed a high-fat diet for 4 weeks, and intravital microscopy of the carotid artery was performed to assess luminal leukocyte endothelial interactions. Myeloid cell subsets were identified by intravenous injection of antibodies to Ly6G, Ly6C, and CD11b 10 minutes before recording. Displayed are quantification of tethering (A), rolling speed (B), and rolling flux (C) 
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In fact, the pattern of alterations in leukocyte adhesion with enhanced adhesion and reduced rolling flux pointed toward a modification of chemokine-mediated leukocyte integrin activation and subsequent firm adhesion.
Annexin A1 Abolishes Chemokine-Mediated Integrin Activation
Integrin activation was further studied in murine myeloid cells after stimulation with CCL2, CCL5, CXCL1, and leukotriene B4 (LTB4), all of which are chemotactic molecules with reported importance in arterial myeloid cell recruitment. Figure IVA and IVB), whereas there was only a trend toward reduction for LTB4-stimulated binding of ICAM-1 (P=0.12).
To study the effect of Ac2-26 on adhesion of human myeloid cells, isolated human monocytes and neutrophils were perfused over tumor necrosis factor-activated human umbilical vein endothelial cells in the absence or in the presence of increasing amounts of Ac2-26 (Online Figure IVF and IVG). In these experiments, the presence of Ac2-26 caused a significant, dose-dependent decrease in myeloid cell adhesion with significant reductions at doses of 10 and 50 μg/mL. With the robust effect of Ac2-26 on CCL5-evoked integrin activation ( Figure 4A and 4B) and the reported importance of CCL5 in arterial recruitment of both neutrophils and monocytes, 13, 14 we limited further mechanistic studies to studying the effect of Ac2-26 on CCL5-evoked integrin activation. Here, we find that Ac2-26 dose dependently reduces the affinity for ICAM-1 and VCAM-1 when neutrophils and classical monocytes are activated with CCL5 ( Figure 4C and 4D ). This response was annulled in myeloid cells harvested from Fpr2 −/− mice ( Figure 4C and 4D) . Full integrin activation is accompanied by a shape change to the fully extended conformation that can be monitored in human cells by the use of antibodies recognizing the activation epitope. Here, Ac2-26 inhibited the CCL5-induced switch of β 2 integrin conformation into its activated state in human neutrophils and monocytes ( Figure 4E ; Online Figure IVH) . In addition, cell surface expression of β 1 and β 2 integrins was neither increased by CCL5 treatment (not shown) nor decreased by Ac2-26 treatment (Online Figure  IVI) . Likewise, Ac2-26 treatment did not affect the expression of the CCL5 receptors, CCR1, CCR3, or CCR5 (Online Figure IVK ). Another well-described aspect of integrin activation is their clustering on the cell surface. Using confocal microscopy, we found that the relatively dispersed distribution of lymphocyte function-associated antigen 1 (LFA1), on mouse neutrophils, as well as on human neutrophils, and monocytes became much more clustered on treatment with CCL5 and that this clustering was strongly reduced by Ac2-26 ( Figure 4F ; Online Figure IVL and IVM). Thus, Ac2-26 inhibits the adhesiveness of myeloid cell β 1 and β 2 integrins by downmodulating their affinity and valency. Chemokine-triggered integrin activation is mediated by an early increase in cytosolic Ca 2+ followed by a later activation of the small GTPase Rap1. 15 To clarify how Ac2-26 interferes with chemokine-driven integrin activation, we analyzed whether either of these 2 steps is affected. Although the treatment of neutrophils with Ac2-26 did not affect the CCL5-stimulated increase in intracellular free Ca 2+ ( Figure 4G ), Ac2-26 treatment reduced CCL5-triggered Rap1 activation in murine neutrophils ( Figure 4H ; Online Figure IVN ) and in human neutrophils and monocytes (Online Figure IVO and IVP), as assessed by measuring the level of GTP-bound Rap1. Thus, Ac2-26 inhibits integrin activation by interfering with the chemokine-driven activation of Rap1, an essential step in integrin activation. To test the involvement of Rap1 in Ac2-26-triggered chemokine-evoked integrin deactivation further, we transferred a wild-type or a constitutively active Rap1 fusion protein into human neutrophils or monocytes before the treatment with Ac2-26 and CCL5. Although the transfer of the fusion proteins did not affect LFA1 activation in response to CCL5 alone, the constitutively active Rap1 fusion protein fully abolished the inhibitory effect of Ac2-26 ( Figure 4E ; Online Figure IVH) , thus confirming that Ac2-26 acts through antagonizing Rap1 activation.
Delivery of the Annexin A1 Fragment Ac2-26 Reduces Atherogenesis
With the powerful abilities of AnxA1 to abrogate integrin activation induced by chemokines, we further aimed at using this knowledge in a translational approach. Hence, we hypothesized that in vivo delivery of Ac2-26 might reduce arterial myeloid cell recruitment. Intravital microscopy in Apoe 
Anxa1
−/− mice was used to study leukocyte dynamics before and after intravenous Ac2-26 injection. To define the optimal time and dose for such experiments, we performed dose-response and time-course analyses using the arterial adhesion of CD11b + myeloid cells to the carotid artery of Apoe −/− mice fed a HFD for 4 weeks as read-out. In these experiments, Ac2-26 at 0.1 and 1 μg was without effect throughout the observation period of ≤30 minutes after Ac2-26 administration. In contrast, Ac2-26 at 10 and 50 μg significantly reduced the number of adherent cells at 10 and 30 minutes after injection (Online Figure VA) . On the basis of this, we decided to study arterial leukocyte adhesion before and 30 minutes after a single dose of Ac2-26 (50 μg). Although Ac2-26 shifted the adherent CD11b + cell fraction in Apoe −/− mice toward the rolling cell fraction, an effect observed even more pronounced in Apoe
−/− mice, this effect was abolished in Apoe
Fpr2
−/− mice ( Figure 5A-5C ). Similar effects were also observed for Ly6G + and Ly6C + cells (Online Figure VB-VE) . In addition, boiled Ac2-26 failed to affect adhesion of myeloid cells (Figure 5A-5C ; Online Figure VB-VE) .
With the potent effect of Ac2-26 to reduce arterial myeloid cell adhesion and to diminish integrin activation evoked by chemokines, we aimed at comparing the effect of Ac2-26 and chemokine receptor antagonists. Because Ac2-26 largely diminished CCL5-evoked integrin activation triggered by CCL2 and CXCL1 to a lower degree, we used specific antagonists to CCR5, CCR2, and CXCR2 to study the effect of Ac2-26 on arterial myeloid cell adhesion. Apoe −/− mice receiving a HFD for 4 weeks were treated with an antagonist to CCR5, CCR2, or CXCR2, a combination of all 3, or vehicle only 30 minutes before intravital microscopy. Adhesion of myeloid cell subsets along the carotid artery was studied before and 30 minutes after intravenous injection of Ac2-26. Although Ac2-26 treatment reduced adhesion of myeloid cell subsets when mice were treated with just 1 chemokine receptor antagonist, this was abrogated in the presence of the combination of antagonists to CCR2, CCR5, and CXCR2 ( Figure 5D ; Online Figure  VF and VG).
These data indicate that Ac2-26 is able to counteract myeloid cell adhesion evoked by various chemokines, and hence we suspected that Ac2-26 should be a powerful tool in reducing early atherosclerotic lesion burden. Thus, we performed a therapeutic experiment with repeated injections of Ac2-26 (3× per week; 50 μg IP per injection) or vehicle control during 4 weeks of HFD. Ac2-26 did not have any obvious side effects and did not alter circulating leukocyte counts or plasma lipid levels (Online Table II ). Histomorphometry of atherosclerotic lesion sizes in aortic root sections, however, revealed a clear-cut reduction in mice receiving Ac2-26 ( Figure 5E ). In line, Ac2-26 administration lowered lesional macrophage counts, whereas neutrophil numbers were low in both groups and Ac2-26 treatment only exerted a trend toward reduction ( Figure 5F and 5G).
Discussion
AnxA1 is a molecule that belongs to a large and structurally heterogeneous family of proresolving molecules. Other family members include resolving lipid mediators, proresolving cytokines, and proresolving hormones. Although these molecules are structurally different they share functional similarities. They terminate inflammatory leukocyte accumulation by
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reducing leukocyte recruitment and enhancing egress; they stimulate clearance of aged and apoptotic cells and actively promote tissue repair. 16 Here, we show that AnxA1 is an endogenous inhibitor of arterial leukocyte recruitment. Because this process is a mechanism essential to atherogenesis, it is not surprising that mice lacking AnxA1 or its receptor FPR2 have accelerated atherosclerosis. Mechanistically, we show that the AnxA1 fragment Ac2-26 counteracts chemokine-mediated integrin activation in neutrophils and monocytes and could hence be a potential tool for the treatment of atherosclerosis. Direct interference with integrins, cell adhesion molecules, or chemokines to prevent arterial leukocyte recruitment has only achieved limited success in translational studies. 17, 18 Reasons for such limitations include the striking redundancy of cell adhesion molecules and chemokines during atherogenic recruitment, rendering interference with just 1 molecule insufficient. Indeed, it has been shown that combined inhibition of chemokine signaling has an additive effect in the treatment of atherosclerosis in mice. 19 By counteracting arterial myeloid cell adhesion instructed by a variety of chemokines, AnxA1-based therapeutic approaches may be superior to the use of individual chemokine receptor antagonists. However, systemic delivery of Ac2-26 may also affect myeloid cell recruitment in acute inflammation and thus impair host defense. Thus, delivery strategies with arterial tropism may be favorable for future translational approaches. 20, 21 Beyond its ability to reduce myeloid cell adhesion, AnxA1 exerts several proresolving effects that may be beneficial during atheroprogression and plaque destabilization. In this context, AnxA1 was identified as a bridging molecule opsonizing apoptotic cells to mediate efferocytosis. 22 In addition, AnxA1 induces a favorable macrophage M2a phenotype, 23 which is 
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Apoe -/-+ αCCR2 + αCCR5 + αCXCR2 characterized by the release of the cytokines interleukin-10 and TGFβ. Thus, AnxA1 and its fragments counteract inflammatory processes of central importance during advanced stages of atherosclerosis, 4 and delivery of AnxA1 fragments may promote plaque stability. Of note, analyses of human atherosclerotic plaques revealed a correlation between lesional AnxA1 and signs of plaque stability. 9 Interestingly, treatment with the annexin family member annexin A5 has been shown to reduce inflammation during advanced stages of atherosclerosis 24 and in models of arterial injury. 25, 26 These indications point toward the possible importance of AnxA1 in plaque stabilization. However, a recent study indicates that mice lacking FPR2 and FPR3 are partially protected from atherosclerosis at a later stage. 27 Thus, subsequent studies are required to define the role of AnxA1 and its therapeutic potential during atheroprogression and plaque destabilization clearly.
An additional point of interest is the origin of AnxA1 in the context of hypercholesterolemia-induced atherosclerosis. Although neutrophils release AnxA1 after establishing interactions with the endothelium, 28 it appears unlikely that neutrophils are a major source during atherogenesis because they have been shown to promote early lesion formation. 13 Instead, we here show that the arterial endothelium expresses large amounts of AnxA1. Given that the interaction between AnxA1 and myeloid cells is likely to occur in the blood or at the interface between blood and the atherosclerotic lesion, the endothelium could be an important source of AnxA1 in atherosclerosis. In fact, it has been shown that endothelial expression of AnxA1 decreases during endothelial dysfunction and vascular inflammation. 29, 30 Interestingly, AnxA1 is primarily a cytosolic protein lacking signal sequences that could direct it into the classical secretory pathway. Nevertheless, AnxA1 can be detected in the plasma under conditions of inflammation or in the supernatant of activated endothelial cells 29, 31 and hence alternative pathways for the secretion of AnxA1 have been proposed. One of these pathways includes the externalization via ABCA1 32 and endothelial expression of this transporter is protective in a mouse model of atherosclerosis. 33 However, additional studies are needed to understand the endogenous source of AnxA1 during hypercholesterolemia.
A striking observation of the here presented study is the differential effect of FPR2 ligands. Although previous work highlighted the proatherogenic role of FPR2 ligands, such as cathelicidin and serum amyloid A, 7, 8 we show that AnxA1exerts antiatherogenic effects. Such opposing effects are not just shown in disease models but have also been reported on a cellular level. For example, acute-phase protein serum amyloid A and cathelicidin mediate FPR2-dependent proinflammatory leukocyte activation, including leukocyte trafficking, cytokine secretion, and inhibition of neutrophil apoptosis. [34] [35] [36] In contrast, AnxA1, Ac2-26, and lipoxin A4 also signal through FPR2 to inhibit leukocyte recruitment, enhance neutrophil apoptosis, and macrophage efferocytosis, 35, 37 key events in inflammatory resolution. Lipid and peptide ligands act with different affinities and bind to distinct pockets on the receptor, thus making a direct competition unlikely. 38 One mechanistic explanation for divergent effects of FPR2 ligands may reside in the ability of FPR2 to form homo-and heterodimers. 39 Although dimerization of G-protein-coupled receptors may not generally be required for ligand recognition, emerging evidence indicates that dimers of G-protein-coupled receptors may affect signaling functions and that ligand selectivity may be directly related to different receptor conformation. 40 FPR2 homodimers and FPR2/FPR1 heterodimers constitutively occur in human leukocytes. 39 In addition, dimer formation and change in receptor conformation can be induced in a ligand-specific fashion, and this does not seem to be simply a consequence of ligandreceptor interaction. As an example, Ac2-26 was found to activate the JNK/caspase-3 pathway, leading to apoptosis in neutrophils. Importantly, this pathway over-rode the apoptosis suppressing action of serum amyloid A and cathelicidin. 39 Recent reports have suggested the tight control of leukocyte recruitment by endogenous inhibitors. In this context, leukocyte-derived pentraxin-3 binds to endothelial P-selectin thereby abrogating leukocyte rolling. 41 Del-1 directly inhibits the interaction of leukocytic LFA1 and ICAM-1. 42 Finally, GDF-15 (growth differentiation factor 15) counteracts chemokine-induced activation of β 2 integrins by interfering with the activity of Rap1-GTPase. 43 Hence, in the context of leukocyte recruitment, the latter molecule seems to share much of its functionality with AnxA1. However, the role of these molecules in atherosclerosis has not been investigated yet. Thus, the presented study is the first report on the role of an endogenous inhibitor of leukocyte recruitment in atherosclerosis. Local delivery of AnxA1, its Ac2-26 fragment, or other endogenous inhibitors of leukocyte recruitment, may harbor valuable opportunities for the prevention and treatment of atherosclerosis.
What Is Known?
• Neutrophils and monocytes enter atherosclerotic lesions in a process involving chemokine-mediated integrin activation.
• Annexin A1 is an endogenous inhibitor of leukocyte recruitment preventing firm adhesion of neutrophils in the microcirculation.
What New Information Does This Article Contribute?
• Annexin A1 and its receptor formyl peptide receptor 2 are protective during early stages of atherosclerosis in Apoe null mice fed a high-fat diet.
• The annexin A1 fragment Ac2-26 inhibits chemokine-evoked integrin activation and with this arterial adhesion of neutrophils and monocytes.
• Repeated treatment with Ac2-26 reduces early atherosclerosis.
Endogenous inhibitors of leukocyte recruitment have been identified as a set of breaks to fine-tune inflammatory leukocyte trafficking. However, their role in atherosclerosis is largely unknown. Here, we show that annexin A1, a protein known to inhibit leukocyte adhesion in microvascular inflammation, and its receptor formyl peptide receptor 2, are protective during early stages of atherosclerosis in Apoe null mice. Mechanistically, the annexin A1 fragment Ac2-26 counteracts chemokine-induced integrin activation, a process important in arterial leukocyte recruitment. Notably, Ac2-26 overrides the chemokine signaling exerted by several chemokines. Hence, Ac2-26 fragment of annexin1 might be of clinical importance in settings where redundant chemokine signaling guides leukocytes to sites of inflammation. (Invitrogen) and 0.5 % BSA (Sigma). Cells were exposed to CCL2 (5 µg/ml), CCL5 (5 µg/ml), 67 CXCL1 (5 µg/ml; all Peprotech), and LTB4 (1 µg/ml, Santa Cruz) or an equal volume of buffer, in the 68 presence of ICAM-1/Fc (5 μg/ml, R&D Systems) or of VCAM-1/Fc (5 μg/ml, R&D Systems) and PE-69 conjugated anti-human IgG1 (1 µg/ml; Fc-specific, Southern Biotechnology) for 5 minutes at 37 °C. 
